Skip to content
2000
Volume 26, Issue 2
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

The alternative splicing (AS) of pre-mRNA is an important process in controlling the expression of human genes, which can enrich the diversity of the proteome and regulate gene function. On the contrary, aberrant splicing contributes significantly to numerous human diseases progression, including tumors, neurological diseases, metabolic diseases, infections, and immune diseases. The PUF60, a protein related to RNA splicing, plays critical functions in RNA splicing and gene transcription regulation. In addition, it can achieve synergistic binding with U2AF65 on RNA through interactions in the pyrimidine region, promoting the splicing of introns with weak 3'- splice sites and pyrimidine bundles. Nevertheless, an increasing amount of evidence supports that it shows a significant overexpression pattern in the vast majority of cancer cells and is crucial for embryonic development, indicating that PUF60 may hold the post of a potential therapeutic target for such diseases. These studies have significantly increased our interest in PUF60. Thus, we briefly reviewed the structural domain characteristics of the PUF60, splicing mutants of PUF60, and the roles and functions in human diseases, including various cancers, infections of bacterium and viruses, myositis, and Verheij syndrome. Furthermore, the targeted PUF60 inhibitors and boundedness of the current research were elaborated in the article. The article effectively communicates critical perception and insight, making it a precious resource for those interested in PUF60 research and treatment.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206346843241119105519
2025-01-03
2026-02-26

  • From This Site

    /content/journals/acamc/10.2174/0118715206346843241119105519
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WangB.D. LeeN. Aberrant RNA splicing in cancer and drug resistance.Cancers2018101145810.3390/cancers10110458 30463359
     [Google Scholar]
  2. WangE.T. SandbergR. LuoS. KhrebtukovaI. ZhangL. MayrC. KingsmoreS.F. SchrothG.P. BurgeC.B. Alternative isoform regulation in human tissue transcriptomes.Nature2008456722147047610.1038/nature07509 18978772
     [Google Scholar]
  3. JeonJ. KimK.T. ChoiJ. CheongK. KoJ. ChoiG. LeeH. LeeG.W. ParkS.Y. KimS. KimS.T. MinC.W. KangS. LeeY.H. Alternative splicing diversifies the transcriptome and proteome of the rice blast fungus during host infection.RNA Biol.202219137338610.1080/15476286.2022.2043040 35311472
     [Google Scholar]
  4. WillC.L. LührmannR. Spliceosomal UsnRNP biogenesis, structure and function.Curr. Opin. Cell Biol.200113329030110.1016/S0955‑0674(00)00211‑8 11343899
     [Google Scholar]
  5. WanR. YanC. BaiR. WangL. HuangM. WongC.C.L. ShiY. The 3.8 Å structure of the U4/U6.U5 tri-snRNP: Insights into spliceosome assembly and catalysis.Science2016351627246647510.1126/science.aad6466 26743623
     [Google Scholar]
  6. UrbanskiL.M. LeclairN. AnczukówO. Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.Wiley Interdiscip. Rev. RNA201894e147610.1002/wrna.1476 29693319
     [Google Scholar]
  7. WangX. HuaJ. LiJ. ZhangJ. DzakahE.E. CaoG. LinW. Mechanisms of non-coding RNA-modulated alternative splicing in cancer.RNA Biol.202219154154710.1080/15476286.2022.2062846
     [Google Scholar]
  8. HuS. WangX. ShanG. Insertion of an Alu element in a lncRNA leads to primate-specific modulation of alternative splicing.Nat. Struct. Mol. Biol.201623111011101910.1038/nsmb.3302 27694840
     [Google Scholar]
  9. WangX. LiJ. BianX. WuC. HuaJ. ChangS. YuT. LiH. LiY. HuS. ShanG. LinW. CircURI1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer.Proc. Natl. Acad. Sci. USA202111833e201288111810.1073/pnas.2012881118 34385309
     [Google Scholar]
  10. YangY. JiaD. KimH. Abd ElmageedZ.Y. DattaA. DavisR. SrivastavS. MorozK. CrawfordB.E. MopartyK. ThomasR. HudsonR.S. AmbsS. Abdel-MageedA.B. Dysregulation of miR-212 promotes castration resistance through hnRNPH1-mediated regulation of AR and AR-V7: Implications for racial disparity of prostate cancer.Clin. Cancer Res.20162271744175610.1158/1078‑0432.CCR‑15‑1606 26553749
     [Google Scholar]
  11. PAGE-McCAW, P.S.; Amonlirdviman, K.; Sharp, P.A. PUF60: A novel U2AF65-related splicing activity.RNA19995121548156010.1017/S1355838299991938 10606266
     [Google Scholar]
  12. KrálovičováJ. ŠevčíkováI. StejskalováE. ObućaM. HillerM. StaněkD. VořechovskýI. PUF60-activated exons uncover altered 3′ splice-site selection by germline missense mutations in a single RRM.Nucleic Acids Res.201846126166618710.1093/nar/gky389 29788428
     [Google Scholar]
  13. KralovicovaJ. BorovskaI. KubickovaM. LukavskyP.J. VorechovskyI. Cancer-associated substitutions in RNA recognition motifs of PUF60 and U2AF65 reveal residues required for correct folding and 3′ splice-ssite sselection.Cancers2020127186510.3390/cancers12071865 32664474
     [Google Scholar]
  14. CorsiniL. SattlerM. Backbone assignment of the UHM domain of Puf60 free and bound to five ligands.Biomol. NMR Assign.20082221121410.1007/s12104‑008‑9123‑7 19636907
     [Google Scholar]
  15. CorsiniL. HothornM. StierG. RybinV. ScheffzekK. GibsonT.J. SattlerM. Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60.J. Biol. Chem.2009284163063910.1074/jbc.M805395200 18974054
     [Google Scholar]
  16. LoerchS. MaucuerA. ManceauV. GreenM.R. KielkopfC.L. Cancer-relevant splicing factor CAPERα engages the essential splicing factor SF3b155 in a specific ternary complex.J. Biol. Chem.201428925173251733710.1074/jbc.M114.558825 24795046
     [Google Scholar]
  17. HastingsM.L. AllemandE. DuelliD.M. MyersM.P. KrainerA.R. Control of pre-mRNA splicing by the general splicing factors PUF60 and U2AF(65).PLoS One200726e53810.1371/journal.pone.0000538 17579712
     [Google Scholar]
  18. LiuJ. HeL. CollinsI. GeH. LibuttiD. LiJ. EglyJ.M. LevensD. The FBP interacting repressor targets TFIIH to inhibit activated transcription.Mol. Cell20005233134110.1016/S1097‑2765(00)80428‑1 10882074
     [Google Scholar]
  19. CukierC.D. HollingworthD. MartinS.R. KellyG. Díaz-MorenoI. RamosA. Molecular basis of FIR-mediated c-myc transcriptional control.Nat. Struct. Mol. Biol.20101791058106410.1038/nsmb.1883 20711187
     [Google Scholar]
  20. CrichlowG.V. ZhouH. HsiaoH. FrederickK.B. DebrosseM. YangY. Folta-StogniewE.J. ChungH.J. FanC. De La CruzE.M. LevensD. LolisE. BraddockD. Dimerization of FIR upon FUSE DNA binding suggests a mechanism of c-myc inhibition.EMBO J.200827127728910.1038/sj.emboj.7601936 18059478
     [Google Scholar]
  21. CrannaN.J. MitchellN.C. HannanR.D. QuinnL.M. Hfp, the Drosophila homolog of the mammalian c-myc transcriptional-repressor and tumor suppressor FIR, inhibits dmyc transcription and cell growth.Fly (Austin)20115212913310.4161/fly.5.2.14482 21245665
     [Google Scholar]
  22. MatsushitaK. TomonagaT. ShimadaH. ShioyaA. HigashiM. MatsubaraH. HarigayaK. NomuraF. LibuttiD. LevensD. OchiaiT. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis.Cancer Res.20066631409141710.1158/0008‑5472.CAN‑04‑4459 16452196
     [Google Scholar]
  23. TanakaN. ArakiK. MizokamiD. MiyagawaY. YamashitaT. TomifujiM. UedaY. InoueM. MatsushitaK. NomuraF. ShimadaH. ShiotaniA. Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.Gene Ther.201522429730410.1038/gt.2014.123 25588744
     [Google Scholar]
  24. KitamuraA. MatsushitaK. TakiguchiY. ShimadaH. TadaY. YamanakaM. HiroshimaK. TagawaM. TomonagaT. MatsubaraH. InoueM. HasegawaM. SatoY. LevensD. TatsumiK. NomuraF. Synergistic effect of non‐transmissible Sendai virus vector encoding the c‐myc suppressor FUSE‐binding protein‐interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.Cancer Sci.201110271366137310.1111/j.1349‑7006.2011.01931.x 21435101
     [Google Scholar]
  25. SveenA. KilpinenS. RuusulehtoA. LotheR.A. SkotheimR.I. Aberrant RNA splicing in cancer; Expression changes and driver mutations of splicing factor genes.Oncogene201635192413242710.1038/onc.2015.318 26300000
     [Google Scholar]
  26. ShuaiS. SuzukiH. Diaz-NavarroA. NadeuF. KumarS.A. Gutierrez-FernandezA. DelgadoJ. PinyolM. López-OtínC. PuenteX.S. TaylorM.D. CampoE. SteinL.D. The U1 spliceosomal RNA is recurrently mutated in multiple cancers.Nature2019574778071271610.1038/s41586‑019‑1651‑z 31597163
     [Google Scholar]
  27. SunD. LeiW. HouX. LiH. NiW. PUF60 accelerates the progression of breast cancer through down-regulation of PTEN expression.Cancer Manag. Res.20191182183010.2147/CMAR.S180242 30697074
     [Google Scholar]
  28. García-CárdenasJ.M. Armendáriz-CastilloI. Pérez-VillaA. IndacocheaA. Jácome-AlvaradoA. López-CortésA. GuerreroS. Integrated in silico analyses identify PUF60 and SF3A3 as new spliceosome-related breast cancer RNA-binding proteins.Biology202211448110.3390/biology11040481 35453681
     [Google Scholar]
  29. AnJ. LuoZ. AnW. CaoD. MaJ. LiuZ. Identification of spliceosome components pivotal to breast cancer survival.RNA Biol.202118683384210.1080/15476286.2020.1822636 32965163
     [Google Scholar]
  30. PengY. WangY. ZhouC. MeiW. ZengC. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway?Front. Oncol.20221281912810.3389/fonc.2022.819128 35402264
     [Google Scholar]
  31. ShiW. HuD. LinS. ZhuoR. Five-mRNA signature for the prognosis of breast cancer based on the ceRNA network.BioMed Res. Int.2020202011710.1155/2020/9081852 32964046
     [Google Scholar]
  32. OguraY. HoshinoT. TanakaN. AilikenG. KobayashiS. KitamuraK. RahmutullaB. KanoM. MurakamiK. AkutsuY. NomuraF. ItogaS. MatsubaraH. MatsushitaK. Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancers.Oncotarget2018933229292294410.18632/oncotarget.25149 29796163
     [Google Scholar]
  33. KobayashiS. HiwasaT. IshigeT. RahmutullaB. KanoM. HoshinoT. MinamotoT. ShimadaH. NomuraF. MatsubaraH. MatsushitaK. Anti‐ FIR Δexon2, a splicing variant form of PUF 60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.Cancer Sci.201911062004201310.1111/cas.14024 30980774
     [Google Scholar]
  34. WelckerM. ClurmanB.E. FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation.Nat. Rev. Cancer200882839310.1038/nrc2290 18094723
     [Google Scholar]
  35. MüllerB. BovetM. YinY. StichelD. MalzM. González-VallinasM. MiddletonA. EhemannV. SchmittJ. MuleyT. MeisterM. HerpelE. SingerS. WarthA. SchirmacherP. DrasdoD. MatthäusF. BreuhahnK. Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non‐small cell lung cancer (NSCLC) cells.J. Pathol.2015237339040110.1002/path.4588 26177862
     [Google Scholar]
  36. XuN. RenY. BaoY. ShenX. KangJ. WangN. WangZ. HanX. LiZ. ZuoJ. WeiG.H. WangZ. ZongW.X. LiuW. XieG. WangY. PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C.Cell Rep.202342911304110.1016/j.celrep.2023.113041 37682709
     [Google Scholar]
  37. BoutrosR. LobjoisV. DucommunB. CDC25 phosphatases in cancer cells: Key players? Good targets?Nat. Rev. Cancer20077749550710.1038/nrc2169 17568790
     [Google Scholar]
  38. LongQ. AnX. ChenM. WangN. SuiS. LiY. ZhangC. LeeK. WangX. TianT. PanY. QiuH. XieF. DengW. ZhengF. HeL. PUF60/AURKA axis contributes to tumor progression and malignant phenotypes in bladder cancer.Front. Oncol.20201056801510.3389/fonc.2020.568015 33117697
     [Google Scholar]
  39. ZhengD. LiJ. YanH. ZhangG. LiW. ChuE. WeiN. Emerging roles of Aurora-A kinase in cancer therapy resistance.Acta Pharm. Sin. B20231372826284310.1016/j.apsb.2023.03.013 37521867
     [Google Scholar]
  40. MalzM. BovetM. SamarinJ. RabenhorstU. StichtC. BissingerM. RoesslerS. BermejoJ.L. RennerM. CalvisiD.F. SingerS. GanzingerM. WeberA. GretzN. ZörnigM. SchirmacherP. BreuhahnK. Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma.Hepatology20146041241125010.1002/hep.27218 24824848
     [Google Scholar]
  41. KajiwaraT. MatsushitaK. ItogaS. TamuraM. TanakaN. TomonagaT. MatsubaraH. ShimadaH. HabaraY. MatsuoM. NomuraF. SAP 155‐mediatedC‐MYC suppressor far‐upstream element‐binding protein‐interacting repressor splicing variants are activated in colon cancer tissues.Cancer Sci.2013104214915610.1111/cas.12058 23113893
     [Google Scholar]
  42. KobayashiS. HoshinoT. HiwasaT. SatohM. RahmutullaB. TsuchidaS. KomukaiY. TanakaT. MatsubaraH. ShimadaH. NomuraF. MatsushitaK. Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients.Oncotarget2016750824938250310.18632/oncotarget.12696 27756887
     [Google Scholar]
  43. YuanX. LarssonC. XuD. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: Old actors and new players.Oncogene201938346172618310.1038/s41388‑019‑0872‑9 31285550
     [Google Scholar]
  44. LongQ. HuaY. HeL. ZhangC. SuiS. LiY. QiuH. TianT. AnX. LuoG. YanY. ZhaoA. ShiD. XieF. ChenM. ZhengF. DengW. Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase.Int. J. Biol. Sci.202016153002301710.7150/ijbs.45115 33061812
     [Google Scholar]
  45. ZhangC. NiX. TaoC. ZhouZ. WangF. GuF. CuiX. JiangS. LiQ. LuH. LiD. WuZ. ZhangR. Targeting PUF60 prevents tumor progression by retarding mRNA decay of oxidative phosphorylation in ovarian cancer.Cell. Oncol.202447115717410.1007/s13402‑023‑00859‑w 37632669
     [Google Scholar]
  46. RamakrishnaM. WilliamsL.H. BoyleS.E. BearfootJ.L. SridharA. SpeedT.P. GorringeK.L. CampbellI.G. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis.PLoS One201054e998310.1371/journal.pone.0009983 20386695
     [Google Scholar]
  47. WangF. PengL. SunY. ZhangB. LuS. PUF60 promotes glioblastoma progression through regulation of EGFR stability.Biochem. Biophys. Res. Commun.2022636Pt 119019610.1016/j.bbrc.2022.10.082 36335869
     [Google Scholar]
  48. ChauhanK. KalamH. DuttR. KumarD. RNA splicing: A new paradigm in host-pathogen interactions.J. Mol. Biol.201943181565157510.1016/j.jmb.2019.03.001 30857970
     [Google Scholar]
  49. KewC. HuangW. FischerJ. GanesanR. RobinsonN. AntebiA. Evolutionarily conserved regulation of immunity by the splicing factor RNP-6/PUF60.eLife20209e5759110.7554/eLife.57591 32538777
     [Google Scholar]
  50. RenC. ChenT. SunH. JiangX. HuC. QianJ. WangY. The first echinoderm poly-U-binding factor 60 kDa (PUF60) from sea cucumber (Stichopus monotuberculatus): Molecular characterization, inducible expression and involvement of apoptosis.Fish Shellfish Immunol.201547119620410.1016/j.fsi.2015.09.001 26362209
     [Google Scholar]
  51. LiW. GuanX. PUF60 of Japanese flounder is regulated by pol-miR-novel_395 and involved in pathogen infection, autophagy, and apoptosis.Dev. Comp. Immunol.202112310417010.1016/j.dci.2021.104170 34144120
     [Google Scholar]
  52. SunS. NakashimaK. ItoM. LiY. ChidaT. TakahashiH. WatashiK. SawasakiT. WakitaT. SuzukiT. Involvement of PUF60 in transcriptional and post-transcriptional regulation of nepatitis B virus pregenomic RNA expression.Sci. Rep.2017711287410.1038/s41598‑017‑12497‑y 28993636
     [Google Scholar]
  53. JonesJ. WortmannR. Idiopathic inflammatory myopathies—a review.Clin. Rheumatol.201534583984410.1007/s10067‑015‑2891‑4 25681070
     [Google Scholar]
  54. ZhangY.M. YangH.B. ShiJ.L. ChenH. ShuX.M. LuX. WangG.C. PengQ.L. The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy.Clin. Rheumatol.20183761573158010.1007/s10067‑018‑4031‑4 29541951
     [Google Scholar]
  55. FiorentinoD.F. PresbyM. BaerA.N. PetriM. RiegerK.E. SoloskiM. RosenA. MammenA.L. Christopher-StineL. Casciola-RosenL. PUF60: A prominent new target of the autoimmune response in dermatomyositis and Sjögren’s syndrome.Ann. Rheum. Dis.20167561145115110.1136/annrheumdis‑2015‑207509 26253095
     [Google Scholar]
  56. XuQ. LiC. WangY. LiH. WuB. JiangY. XuX. Role of PUF60 gene in Verheij syndrome: A case report of the first Chinese Han patient with a de novo pathogenic variant and review of the literature.BMC Med. Genomics20181119210.1186/s12920‑018‑0421‑3 30352594
     [Google Scholar]
  57. YamadaM. UeharaT. SuzukiH. TakenouchiT. KosakiK. Protein elongation variant of PUF60: Milder phenotypic end of the Verheij syndrome.Am. J. Med. Genet. A.2020182112709271410.1002/ajmg.a.61816 32851780
     [Google Scholar]
  58. LatypovaX. DangX. ZhangJ. IsidorB. Letter regarding the article “two girls with short stature, short neck, vertebral anomalies, Sprengel deformity and intellectual disability” (Isidor et al., 2015).Eur. J. Med. Genet.202164410417910.1016/j.ejmg.2021.104179 33636376
     [Google Scholar]
  59. DauberA. GolzioC. GuenotC. JodelkaF.M. KibaekM. KjaergaardS. LeheupB. MartinetD. NowaczykM.J.M. RosenfeldJ.A. ZeesmanS. ZunichJ. BeckmannJ.S. HirschhornJ.N. HastingsM.L. JacquemontS. KatsanisN. SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copy-number variant.Am. J. Hum. Genet.201393579881110.1016/j.ajhg.2013.09.010 24140112
     [Google Scholar]
  60. HoogenboomA. FalixF.A. van der LaanL. KerkhofJ. AldersM. SadikovicB. van HaelstM.M. Novel PUF60 variant suggesting an interaction between Verheij and Cornelia de Lange syndrome: Phenotype description and review of the literature.Eur. J. Hum. Genet.202432443543910.1038/s41431‑023‑01527‑1 38273166
     [Google Scholar]
  61. El ChehadehS. Kerstjens-FrederikseW.S. ThevenonJ. KuentzP. BruelA.L. Thauvin-RobinetC. BensignorC. DollfusH. LaugelV. RivièreJ.B. DuffourdY. BonnetC. RobertM.P. IsaikoR. StraubM. Creuzot-GarcherC. CalvasP. ChassaingN. LoeysB. ReyniersE. VandeweyerG. KooyF. HančárováM. HavlovicováM. PrchalováD. SedláčekZ. GilissenC. PfundtR. Wassink-RuiterJ.S.K. FaivreL. Dominant variants in the splicing factor PUF60 cause a recognizable syndrome with intellectual disability, heart defects and short stature.Eur. J. Hum. Genet.2017251435110.1038/ejhg.2016.133 27804958
     [Google Scholar]
  62. MiaoM. WangJ. GuoC. SuX. SunL. LuS. Identification of a novel de novo PUF60 variant causing Verheij syndrome in a fetus.Gene202489714809210.1016/j.gene.2023.148092 38110042
     [Google Scholar]
  63. OgawaT. XueJ. GuoL. Inoue-AraiM.S. Vendramini-PittoliS. Zechi-CeideR.M. Candido-SouzaR.M. TonelloC. BrandãoM.M. OzawaT.O. PeixotoA.P. RuizD.M.C.F. NakashimaT. IkegawaS. MoriyamaK. Kokitsu-NakataN.M. Identification of a de novo PUF60 variant associated with craniofacial microsomia.Am. J. Med. Genet. A.20241949e6363110.1002/ajmg.a.63631 38647383
     [Google Scholar]
  64. CorsiniL. BonnalS. BasquinJ. HothornM. ScheffzekK. ValcárcelJ. SattlerM. U2AF-homology motif interactions are required for alternative splicing regulation by SPF45.Nat. Struct. Mol. Biol.200714762062910.1038/nsmb1260 17589525
     [Google Scholar]
  65. JagtapP.K.A. KubelkaT. SoniK. WillC.L. GargD. SippelC. KappT.G. PotukuchiH.K. SchorppK. HadianK. KesslerH. LührmannR. HauschF. BachT. SattlerM. Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly.Nat. Commun.2020111562110.1038/s41467‑020‑19514‑1 33159082
     [Google Scholar]
  66. ZhangR. ZhangC.C. ZhangZ.G. ChenY.H. GuoW.K. Preparation of t-butoxycarbonyl heteroaryl compound as PUF60 inhibitors and antitumor agents. C.N.Patent 113149980A,2020
     [Google Scholar]
  67. ZhangC.C. Study on the Mechanism of PUF60 Promoting the Development of Ovarian Cancer and the Effectiveness of Its Small Molecule Inhibitors.Southern Medical University2020
     [Google Scholar]
  68. InoueD. ChewG.L. LiuB. MichelB.C. PangalloJ. D’AvinoA.R. HitchmanT. NorthK. LeeS.C.W. BitnerL. BlockA. MooreA.R. YoshimiA. Escobar-HoyosL. ChoH. PensonA. LuS.X. TaylorJ. ChenY. KadochC. Abdel-WahabO. BradleyR.K. Spliceosomal disruption of the non-canonical BAF complex in cancer.Nature2019574777843243610.1038/s41586‑019‑1646‑9 31597964
     [Google Scholar]
  69. ZhaoZ. XuQ. WeiR. HuangL. WangW. WeiG. NiT. Comprehensive characterization of somatic variants associated with intronic polyadenylation in human cancers.Nucleic Acids Res.20214918103691038110.1093/nar/gkab772 34508351
     [Google Scholar]
  70. WanL. LinK.T. RahmanM.A. IshigamiY. WangZ. JensenM.A. WilkinsonJ.E. ParkY. TuvesonD.A. KrainerA.R. Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer.Cancer Discov.20231371678169510.1158/2159‑8290.CD‑22‑1013 37098965
     [Google Scholar]
  71. AilikenG. KitamuraK. HoshinoT. SatohM. TanakaN. MinamotoT. RahmutullaB. KobayashiS. KanoM. TanakaT. KanedaA. NomuraF. MatsubaraH. MatsushitaK. Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancer.Oncogenesis2020922610.1038/s41389‑020‑0205‑4 32071290
     [Google Scholar]
  72. KitamuraK. HoshinoT. OkabeA. FukuyoM. RahmutullaB. TanakaN. KobayashiS. TanakaT. ShidaT. UedaM. MinamotoT. MatsubaraH. KanedaA. IshiiH. MatsushitaK. The link of mRNA and rRNA transcription by PUF60/FIR through TFIIH/P62 as a novel therapeutic target for cancer.Int. J. Mol. Sci.202324241734110.3390/ijms242417341 38139171
     [Google Scholar]
  73. MatsushitaK. KitamuraK. RahmutullaB. TanakaN. IshigeT. SatohM. HoshinoT. MiyagiS. MoriT. ItogaS. ShimadaH. TomonagaT. KitoM. Nakajima-TakagiY. KuboS. NakasekoC. HatanoM. MikiT. MatsuoM. FukuyoM. KanedaA. IwamaA. NomuraF. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.Oncotarget2015675102511710.18632/oncotarget.3244 25671302
     [Google Scholar]
  74. LowK.J. AnsariM. Abou JamraR. ClarkeA. El ChehadehS. FitzPatrickD.R. GreensladeM. HendersonA. HurstJ. KellerK. KuentzP. PrescottT. RoesslerF. SelmerK.K. SchneiderM.C. StewartF. Tatton-BrownK. ThevenonJ. VigelandM.D. VogtJ. WillemsM. ZonanaJ. StudyD.D.D. SmithsonS.F. PUF60 variants cause a syndrome of ID, short stature, microcephaly, coloboma, craniofacial, cardiac, renal and spinal features.Eur. J. Hum. Genet.201725555255910.1038/ejhg.2017.27 28327570
     [Google Scholar]
  75. ThirumalaivasanN. KanagarajK. LogeshK. ChandrasekaranS. KumarS. SubramanianR. SenthilkumarN. KumarA. AngadiV.J.A. A Al-KahtaniA. Exploring luminescent carbon dots derived from syrup bottle waste and curcumin for potential antimicrobial and bioimaging applications.Chemosphere202435414159210.1016/j.chemosphere.2024.141592 38467196
     [Google Scholar]
  76. ThirumalaivasanN. GnanasekaranL. KumarS. DurvasuluR. SundaramT. RajendranS. NanganS. KanagarajK. Utilization of fungal and bacterial bioremediation techniques for the treatment of toxic waste and biowaste.Front. Mater.202411141644510.3389/fmats.2024.1416445
     [Google Scholar]
  77. ThirumalaivasanN. GopiS. KarthikK. NanganS. KanagarajK. RajendranS. Nano-PCM materials: Bridging the gap in energy storage under fluctuating environmental conditions.Process Saf. Environ. Prot.20241891003102110.1016/j.psep.2024.06.079
     [Google Scholar]
  78. HuangW. KewC. FernandesS.A. LöhrkeA. HanL. DemetriadesC. AntebiA. Decreased spliceosome fidelity and egl-8 intron retention inhibit mTORC1 signaling to promote longevity.Nature Aging20222979680810.1038/s43587‑022‑00275‑z 37118503
     [Google Scholar]
  79. LiM. RenC. ZhouS. HeY. GuoY. ZhangH. LiuL. CaoQ. WangC. HuangJ. HuY. BaiX. GuoX. ShuW. HuoR. Integrative proteome analysis implicates aberrant RNA splicing in impaired developmental potential of aged mouse oocytes.Aging Cell20212010e1348210.1111/acel.13482 34582091
     [Google Scholar]
  80. HanzawaH. ShimadaT. TakahashiM. TakahashiH. Revisiting biomolecular NMR spectroscopy for promoting small-molecule drug discovery.J. Biomol. NMR20207410-1150150810.1007/s10858‑020‑00314‑0 32306215
     [Google Scholar]
  81. KangZ. LiS. LiY. SongJ. PengY. ChenY. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024).Chin. Chem. Lett.20243511044710.1016/j.cclet.2024.110447
     [Google Scholar]
  82. MizuguchiH. ItoT. NishidaK. WakugawaT. NakanoT. TanabeA. WatanoT. KitamuraN. KaminumaO. KimuraK. IshidaT. MatsunagaA. OhtaK. ShimonoR. KutsunaH. YasudaT. YabumotoM. KitamuraY. TakedaN. FukuiH. Structure-activity relationship studies of pyrogallol as a calcineurin/NFAT signaling suppressor.J. Pharmacol. Sci.2024155414014710.1016/j.jphs.2024.06.002 38880548
     [Google Scholar]
/content/journals/acamc/10.2174/0118715206346843241119105519
Loading
The Function of Poly (U) Binding Splicing Factor 60 (PUF60) in Disease Regulation
Anti-Cancer Agents in Medicinal Chemistry 26, 137 (2026); https://doi.org/10.2174/0118715206346843241119105519
/content/journals/acamc/10.2174/0118715206346843241119105519
/content/journals/acamc/10.2174/0118715206346843241119105519
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): alternative splicing of pre-mRNA; cancer; FIR; FIRΔexon2; PUF60; verheij syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test